Quanterix Corp- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Quanterix Corp 公司

Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.

Quanterix Corp簡介



公司代碼QTRX

公司名稱Quanterix Corp

上市日期Dec 07, 2017

CEOToloue (Masoud)

員工數量471

證券類型Ordinary Share

年結日Dec 07

公司地址900 Middlesex Turnpike

城市BILLERICA

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編01821

電話16173019400

網址https://www.quanterix.com/

公司代碼QTRX

上市日期Dec 07, 2017

CEOToloue (Masoud)

Quanterix Corp公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Masoud Toloue, Ph.D.

President, Chief Executive Officer, Director

355.02K

+20.48%

Mr. William P. (Bill) Donnelly

Executive Chairman of the Board

154.13K

+8.83%

Ms. Karen A. Flynn

Independent Director

33.84K

-47.10%

Ms. Vandana Sriram, CPA

Chief Financial Officer, Treasurer

32.38K

+64.05%

Mr. Scott Mendel

Director

12.35K

-155.84%

Mr. Jeffrey Thomas (Jeff) Elliott

Lead Independent Director

11.39K

-139.92%

Dr. Myla P. Lai-Goldman, M.D.

Director

6.97K

-335.42%

Dr. Ivana Magov Evi-liebisch, J.D., Ph.D.

Independent Director

--

Dr. Garret Hampton, Ph.D.

Independent Director

--

Dr. Alan Sachs, M.D., Ph.D.

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Masoud Toloue, Ph.D.

President, Chief Executive Officer, Director

355.02K

+20.48%

Mr. William P. (Bill) Donnelly

Executive Chairman of the Board

154.13K

+8.83%

Ms. Karen A. Flynn

Independent Director

33.84K

-47.10%

Ms. Vandana Sriram, CPA

Chief Financial Officer, Treasurer

32.38K

+64.05%

Mr. Scott Mendel

Director

12.35K

-155.84%

Mr. Jeffrey Thomas (Jeff) Elliott

Lead Independent Director

11.39K

-139.92%

收入明細

單位: USD更新時間: 4月6日週一

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q2

FY2024Q1

FY2023

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

Product revenue

92.94M

67.03%

Service and other revenue

44.21M

31.89%

Collaboration and license revenue

1.50M

1.08%

地區USD

名稱

營收

佔比

North America

85.11M

61.39%

EMEA

36.72M

26.48%

Asia Pacific

16.82M

12.13%

業務

地區

業務USD

名稱

營收

佔比

Product revenue

92.94M

67.03%

Service and other revenue

44.21M

31.89%

Collaboration and license revenue

1.50M

1.08%

股東統計

更新時間: 5月13日週三

持股股東

股東類型

持股股東

佔比

Portolan Capital Management, L.L.C.

9.61%

Columbia Threadneedle Investments (UK)

6.63%

BlackRock Institutional Trust Company, N.A.

6.55%

Telegraph Hill Partners

5.32%

Blue Water Life Science Advisors, LP.

4.44%

其他

67.46%

持股股東

佔比

Portolan Capital Management, L.L.C.

9.61%

Columbia Threadneedle Investments (UK)

6.63%

BlackRock Institutional Trust Company, N.A.

6.55%

Telegraph Hill Partners

5.32%

Blue Water Life Science Advisors, LP.

4.44%

其他

67.46%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

42.18%

Investment Advisor

21.12%

Hedge Fund

10.89%

Individual Investor

6.28%

Private Equity

5.32%

Research Firm

3.36%

Pension Fund

0.33%

Venture Capital

0.16%

Bank and Trust

0.15%

其他

10.21%

機構持股



更新時間: 4月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2026Q1

371

42.63M

90.49%

-4.98M

2025Q4

383

38.38M

82.16%

-7.31M

2025Q3

384

34.11M

73.41%

-9.53M

2025Q2

391

36.46M

81.18%

-12.95M

2025Q1

401

40.45M

104.19%

-6.42M

2024Q4

388

38.02M

98.63%

-6.28M

2024Q3

386

36.47M

95.03%

-5.94M

2024Q2

394

35.66M

93.20%

-9.57M

2024Q1

395

35.56M

93.43%

-9.17M

2023Q4

388

34.77M

91.99%

-10.35M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Portolan Capital Management, L.L.C.

4.26M

9.12%

+626.23K

+17.23%

Sep 30, 2025

Columbia Threadneedle Investments (UK)

3.14M

6.71%

+8.77K

+0.28%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

2.86M

6.12%

+212.22K

+8.01%

Sep 30, 2025

Telegraph Hill Partners

2.50M

5.36%

+2.50M

--

Sep 30, 2025

Blue Water Life Science Advisors, LP.

957.75K

2.05%

--

Sep 30, 2025

William Blair Investment Management, LLC

1.32M

2.82%

+187.30K

+16.60%

Sep 30, 2025

Walt (David R)

1.86M

3.99%

+2.59K

+0.14%

Oct 01, 2025

Columbia Threadneedle Investments (US)

1.11M

2.37%

-2.14K

-0.19%

Sep 30, 2025

Invenomic Capital Management LP

1.39M

2.98%

+248.10K

+21.67%

Sep 30, 2025

持股ETF



更新時間: 12月2日週二

機構名稱

佔比

Invesco NASDAQ Future Gen 200 ETF

0.63%

iShares Micro-Cap ETF

0.04%

Fidelity Enhanced Small Cap ETF

0.03%

Avantis US Small Cap Equity ETF

0.03%

Invesco RAFI US 1500 Small-Mid ETF

0.02%

iShares Biotechnology ETF

0.02%

Proshares Ultra Russell 2000

0.01%

ProShares UltraPro Russell2000

0.01%

iShares Russell 2000 Value ETF

0.01%

Global X Russell 2000 ETF

0.01%

Invesco NASDAQ Future Gen 200 ETF

佔比0.63%

iShares Micro-Cap ETF

佔比0.04%

Fidelity Enhanced Small Cap ETF

佔比0.03%

Avantis US Small Cap Equity ETF

佔比0.03%

Invesco RAFI US 1500 Small-Mid ETF

佔比0.02%

iShares Biotechnology ETF

佔比0.02%

Proshares Ultra Russell 2000

佔比0.01%

ProShares UltraPro Russell2000

佔比0.01%

iShares Russell 2000 Value ETF

佔比0.01%

Global X Russell 2000 ETF

佔比0.01%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據